253 related articles for article (PubMed ID: 32977539)
21. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
Barbayianni E; Kaffe E; Aidinis V; Kokotos G
Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
[TBL] [Abstract][Full Text] [Related]
22. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
24. The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life.
Katsifa A; Kaffe E; Nikolaidou-Katsaridou N; Economides AN; Newbigging S; McKerlie C; Aidinis V
PLoS One; 2015; 10(11):e0143083. PubMed ID: 26569406
[TBL] [Abstract][Full Text] [Related]
25. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
26. Autotaxin in Pathophysiology and Pulmonary Fibrosis.
Ninou I; Magkrioti C; Aidinis V
Front Med (Lausanne); 2018; 5():180. PubMed ID: 29951481
[TBL] [Abstract][Full Text] [Related]
27. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†.
Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H
Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652
[TBL] [Abstract][Full Text] [Related]
29. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
[TBL] [Abstract][Full Text] [Related]
30. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
31. Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.
Banerjee S; Norman DD; Deng S; Fakayode SO; Lee SC; Parrill AL; Li W; Miller DD; Tigyi GJ
Bioorg Chem; 2020 Oct; 103():104188. PubMed ID: 32890995
[TBL] [Abstract][Full Text] [Related]
32. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis.
Oikonomou N; Mouratis MA; Tzouvelekis A; Kaffe E; Valavanis C; Vilaras G; Karameris A; Prestwich GD; Bouros D; Aidinis V
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):566-74. PubMed ID: 22744859
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
[TBL] [Abstract][Full Text] [Related]
35. Hepatocyte autotaxin expression promotes liver fibrosis and cancer.
Kaffe E; Katsifa A; Xylourgidis N; Ninou I; Zannikou M; Harokopos V; Foka P; Dimitriadis A; Evangelou K; Moulas AN; Georgopoulou U; Gorgoulis VG; Dalekos GN; Aidinis V
Hepatology; 2017 Apr; 65(4):1369-1383. PubMed ID: 27981605
[TBL] [Abstract][Full Text] [Related]
36. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
37. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.
Magkrioti C; Oikonomou N; Kaffe E; Mouratis MA; Xylourgidis N; Barbayianni I; Megadoukas P; Harokopos V; Valavanis C; Chun J; Kosma A; Stathopoulos GT; Bouros E; Bouros D; Syrigos K; Aidinis V
Cancer Res; 2018 Jul; 78(13):3634-3644. PubMed ID: 29724718
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL
J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977
[TBL] [Abstract][Full Text] [Related]
39. Ligand-based autotaxin pharmacophore models reflect structure-based docking results.
Mize CD; Abbott AM; Gacasan SB; Parrill AL; Baker DL
J Mol Graph Model; 2011 Nov; 31():76-86. PubMed ID: 21967734
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M
Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
